STERIS CEO dubs the deal the company’s “most significant” in a long time.
The deal is anticipated to close by the third quarter of 2012.
Senator puts pressure on FDA to explain itself.
New owner pledges growth.
The conference will focus on local companies and connect industry players.
BD will gain a line of anti-needlestick devices.
The new R&D center will focus on the cardiovascular and neuromodulation markets.
Please visit our sister sites:
The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.